FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104927019> ?p ?o ?g. }

• W2104927019 abstract "Although reperfusion injury has been shown to be responsible for cardiomyocytes death after an acute myocardial infarction, there is currently no drug on the market that reduces this type of injury. TRO40303 is a new cardioprotective compound that was shown to inhibit the opening of the mitochondrial permeability transition pore and reduce infarct size after ischemia-reperfusion in a rat model of cardiac ischemia-reperfusion injury.In the rat model, the therapeutic window and the dose effect relationship were investigated in order to select the proper dose and design for clinical investigations. To evaluate post-ischemic functional recovery, TRO40303 was tested in a model of isolated rat heart. Additionally, TRO40303 was investigated in a Phase I randomized, double-blind, placebo controlled study to assess the safety, tolerability and pharmacokinetics of single intravenous ascending doses of the compound (0.5 to 13 mg/kg) in 72 healthy male, post-menopausal and hysterectomized female subjects at flow rates from 0.04 to 35 mL/min (EudraCT number: 2010-021453-39). This work was supported in part by the French Agence Nationale de la Recherche.In the vivo model, TRO40303 reduced infarct size by 40% at 1 mg/kg and by 50% at 3 and 10 mg/kg given by intravenous bolus and was only active when administered before reperfusion. Additionally, TRO40303 provided functional recovery and reduced oxidative stress in the isolated rat heart model.These results, together with pharmacokinetic based allometry to human and non-clinical toxicology data, were used to design the Phase I trial. All the tested doses and flow rates were well tolerated clinically. There were no serious adverse events reported. No relevant changes in vital signs, electrocardiogram parameters, laboratory tests or physical examinations were observed at any time in any dose group. Pharmacokinetics was linear up to 6 mg/kg and slightly ~1.5-fold, hyper-proportional from 6 to 13 mg/kg.These data demonstrated that TRO40303 can be safely administered by the intravenous route in humans at doses expected to be pharmacologically active. These results allowed evaluating the expected active dose in human at 6 mg/kg, used in a Phase II proof-of-concept study currently ongoing." @default.
• W2104927019 created "2016-06-24" @default.
• W2104927019 creator A5010916343 @default.
• W2104927019 creator A5015613180 @default.
• W2104927019 creator A5018326743 @default.
• W2104927019 creator A5038098039 @default.
• W2104927019 creator A5043095356 @default.
• W2104927019 creator A5043655688 @default.
• W2104927019 creator A5046989894 @default.
• W2104927019 creator A5052646795 @default.
• W2104927019 creator A5054592294 @default.
• W2104927019 creator A5060100561 @default.
• W2104927019 creator A5066698835 @default.
• W2104927019 creator A5072900620 @default.
• W2104927019 creator A5073414700 @default.
• W2104927019 creator A5076432544 @default.
• W2104927019 creator A5079874254 @default.
• W2104927019 creator A5086329046 @default.
• W2104927019 date "2014-02-07" @default.
• W2104927019 modified "2023-10-01" @default.
• W2104927019 title "Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial" @default.
• W2104927019 cites W1553636657 @default.
• W2104927019 cites W1983474324 @default.
• W2104927019 cites W2023268971 @default.
• W2104927019 cites W2040454389 @default.
• W2104927019 cites W2043355876 @default.
• W2104927019 cites W2075020461 @default.
• W2104927019 cites W2084789091 @default.
• W2104927019 cites W2089522072 @default.
• W2104927019 cites W2092438446 @default.
• W2104927019 cites W2106088947 @default.
• W2104927019 cites W2106607991 @default.
• W2104927019 cites W2107891011 @default.
• W2104927019 cites W2111686526 @default.
• W2104927019 cites W2111993560 @default.
• W2104927019 cites W2113014582 @default.
• W2104927019 cites W2117630918 @default.
• W2104927019 cites W2119265826 @default.
• W2104927019 cites W2120450006 @default.
• W2104927019 cites W2123218036 @default.
• W2104927019 cites W2123366113 @default.
• W2104927019 cites W2125846158 @default.
• W2104927019 cites W2131015734 @default.
• W2104927019 cites W2132679226 @default.
• W2104927019 cites W2137429382 @default.
• W2104927019 cites W2153082215 @default.
• W2104927019 cites W2153298328 @default.
• W2104927019 cites W2170352109 @default.
• W2104927019 cites W2312388685 @default.
• W2104927019 cites W4243240123 @default.
• W2104927019 doi "https://doi.org/10.1186/1479-5876-12-38" @default.
• W2104927019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3923730" @default.
• W2104927019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24507657" @default.
• W2104927019 hasPublicationYear "2014" @default.
• W2104927019 type Work @default.
• W2104927019 sameAs 2104927019 @default.
• W2104927019 citedByCount "25" @default.
• W2104927019 countsByYear W21049270192014 @default.
• W2104927019 countsByYear W21049270192015 @default.
• W2104927019 countsByYear W21049270192016 @default.
• W2104927019 countsByYear W21049270192017 @default.
• W2104927019 countsByYear W21049270192018 @default.
• W2104927019 countsByYear W21049270192019 @default.
• W2104927019 countsByYear W21049270192020 @default.
• W2104927019 countsByYear W21049270192023 @default.
• W2104927019 crossrefType "journal-article" @default.
• W2104927019 hasAuthorship W2104927019A5010916343 @default.
• W2104927019 hasAuthorship W2104927019A5015613180 @default.
• W2104927019 hasAuthorship W2104927019A5018326743 @default.
• W2104927019 hasAuthorship W2104927019A5038098039 @default.
• W2104927019 hasAuthorship W2104927019A5043095356 @default.
• W2104927019 hasAuthorship W2104927019A5043655688 @default.
• W2104927019 hasAuthorship W2104927019A5046989894 @default.
• W2104927019 hasAuthorship W2104927019A5052646795 @default.
• W2104927019 hasAuthorship W2104927019A5054592294 @default.
• W2104927019 hasAuthorship W2104927019A5060100561 @default.
• W2104927019 hasAuthorship W2104927019A5066698835 @default.
• W2104927019 hasAuthorship W2104927019A5072900620 @default.
• W2104927019 hasAuthorship W2104927019A5073414700 @default.
• W2104927019 hasAuthorship W2104927019A5076432544 @default.
• W2104927019 hasAuthorship W2104927019A5079874254 @default.
• W2104927019 hasAuthorship W2104927019A5086329046 @default.
• W2104927019 hasBestOaLocation W21049270191 @default.
• W2104927019 hasConcept C112705442 @default.
• W2104927019 hasConcept C126322002 @default.
• W2104927019 hasConcept C13591479 @default.
• W2104927019 hasConcept C142724271 @default.
• W2104927019 hasConcept C164705383 @default.
• W2104927019 hasConcept C185592680 @default.
• W2104927019 hasConcept C190283241 @default.
• W2104927019 hasConcept C197934379 @default.
• W2104927019 hasConcept C204787440 @default.
• W2104927019 hasConcept C27081682 @default.
• W2104927019 hasConcept C2777798775 @default.
• W2104927019 hasConcept C2778375690 @default.
• W2104927019 hasConcept C2779676291 @default.
• W2104927019 hasConcept C2780114680 @default.
• W2104927019 hasConcept C31573885 @default.
• W2104927019 hasConcept C42219234 @default.
• W2104927019 hasConcept C43376680 @default.

• next